Rosuvastatin treatment affects both basal and glucose-induced insulin secretion in INS-1 832/13 cells

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  Salunkhe, Vishal A ^a   Elvstam, Olof ^a   Eliasson, Lena ^a   Wendt, Anna ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ION; CHOLESTEROL; DIAZOXIDE; GLUCOSE; MEVALONIC ACID; ROSUVASTATIN; SQUALENE; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; CALCIUM; CALCIUM CHANNEL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; VASODILATOR AGENT;

ANIMAL CELL; ARTICLE; BIOSYNTHESIS; CALCIUM CURRENT; CELL MEMBRANE DEPOLARIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; EXOCYTOSIS; INSULIN RELEASE; NONHUMAN; PANCREAS ISLET BETA CELL; PATCH CLAMP TECHNIQUE; SIGNAL TRANSDUCTION; STIMULUS SECRETION COUPLING; ANIMAL; CELL LINE; CHANNEL GATING; DOSE RESPONSE; DRUG EFFECT; MEMBRANE POTENTIAL; METABOLISM; RAT;

ANIMALS; CALCIUM; CALCIUM CHANNELS; CELL LINE; DIAZOXIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOSE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSULIN; INSULIN SECRETION; INSULIN-SECRETING CELLS; ION CHANNEL GATING; KATP CHANNELS; MEMBRANE POTENTIALS; MEVALONIC ACID; PATCH-CLAMP TECHNIQUES; RATS; ROSUVASTATIN CALCIUM; VASODILATOR AGENTS;

EID: 84978159519     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0151592     Document Type: Article

References (34)

1. Armitage J. The safety of statins in clinical practice. The Lancet. 370(9601):1781-90. doi: 10.1016/S0140-6736(07)60716-8
2. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008; 359(21):2195-207. doi: 10.1056/NEJMoa0807646 PMID: 18997196.
3. Navarese EP, Buffon A, Andreotti F, Kozinski M, Welton N, Fabiszak T, et al. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. The American journal of cardiology. 2013; 111(8):1123-30. doi: 10.1016/j.amjcard.2012.12.037 PMID: 23352266.
4. Kitamura S, Maeda K, Wang Y, Sugiyama Y. Involvement of Multiple Transporters in the Hepatobiliary Transport of Rosuvastatin. Drug Metabolism and Disposition. 2008; 36(10):2014-23. doi: 10.1124/dmd.108.021410 PMID: 18617601
5. White CM. A Review of the Pharmacologic and Pharmacokinetic Aspects of Rosuvastatin. The Journal of Clinical Pharmacology. 2002; 42(9):963-70. PMID: 12211221
6. Meyer zu Schwabedissen HE, Boettcher K, Steiner T, Schwarz UI, Keiser M, Kroemer HK, et al. OATP1B3 Is Expressed in Pancreatic β-Islet Cells and Enhances the Insulinotropic Effect of the Sulfonylurea Derivative Glibenclamide. Diabetes. 2014; 63(2):775-84. doi: 10.2337/db13-1005 PMID: 24150606
7. Koh KK, Sakuma I, Quon MJ. Differential metabolic effects of distinct statins. Atherosclerosis. 2011; 215(1):1-8. doi: 10.1016/j.atherosclerosis.2010.10.036 PMID: 21130454
8. Henquin J-C. The dual control of insulin secretion by glucose involves triggering and amplifying pathways in β-cells. Diabetes Research and Clinical Practice. 2011; 93, Supplement 1:S27-S31. doi: 10.1016/S0168-8227(11)70010-9
9. Ahren B. Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. Nat Rev Drug Discov. 2009; 8(5):369-85. doi: 10.1038/nrd2782 PMID: 19365392
10. Cederberg H, Laakso M. Variable effects of statins on glucose homeostasis parameters and their diabetogenic role. Reply to Kostapanos MS, Agouridis AP and Elisaf MS [letter]. Diabetologia. 2015; 58(8):1962-3. doi: 10.1007/s00125-015-3674-9 PMID: 26109215.
11. Cederberg H, Stancakova A, Yaluri N, Modi S, Kuusisto J, Laakso M. Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort. Diabetologia. 2015; 58(5):1109-17. doi: 10.1007/s00125-015-3528-5 PMID: 25754552.
12. Yada T, Nakata M, Shiraishi T, Kakei M. Inhibition by simvastatin, but not pravastatin, of glucoseinduced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells. Br J Pharmacol. 1999; 126(5):1205-13. doi: 10.1038/sj.bjp.0702397 PMID: 10205010; PubMed Central PMCID: PMC1565875.
13. Li G, Regazzi R, Roche E, Wollheim CB. Blockade of mevalonate production by lovastatin attenuates bombesin and vasopressin potentiation of nutrient-induced insulin secretion in HIT-T15 cells. Probable involvement of small GTP-binding proteins. Biochemical Journal. 1993; 289(Pt 2):379-85. PMC1132178. PMID: 8424783
14. Sampson UK, Linton MF, Fazio S. Are statins diabetogenic? Current opinion in cardiology. 2011; 26(4):342-7. doi: 10.1097/HCO.0b013e3283470359 PMC3341610. PMID: 21499090
15. Hohmeier HE, Mulder H, Chen G, Henkel-Rieger R, Prentki M, Newgard CB. Isolation of INS-1-derived cell lines with robust ATP-sensitive K+ channel-dependent and -independent glucose-stimulated insulin secretion. Diabetes. 2000; 49(3):424-30. Epub 2000/06/27. PMID: 10868964.
16. Salunkhe VA, Esguerra JL, Ofori JK, Mollet IG, Braun M, Stoffel M, et al. Modulation of microRNA-375 expression alters voltage-gated Na channel properties and exocytosis in insulin-secreting cells. Acta physiologica. 2015. doi: 10.1111/apha.12460 PMID: 25627423.
17. Ammala C, Eliasson L, Bokvist K, Larsson O, Ashcroft FM, Rorsman P. Exocytosis elicited by action potentials and voltage-clamp calcium currents in individual mouse pancreatic B-cells. J Physiol. 1993; 472:665-88. PMID: 8145165.
18. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990; 343(6257):425-30. doi: 10.1038/343425a0 PMID: 1967820.
19. Ishikawa M, Okajima F, Inoue N, Motomura K, Kato T, Takahashi A, et al. Distinct effects of pravastatin, atorvastatin, and simvastatin on insulin secretion from a beta-cell line, MIN6 cells. Journal of atherosclerosis and thrombosis. 2006; 13(6):329-35. PMID: 17192698.
20. Del Prato S, Marchetti P, Bonadonna RC. Phasic insulin release and metabolic regulation in type 2 diabetes. Diabetes. 2002; 51 Suppl 1:S109-16. PMID: 11815468.
21. Corkey BE. Diabetes: Have We Got It All Wrong?: Insulin hypersecretion and food additives: cause of obesity and diabetes? Diabetes Care. 2012; 35(12):2432-7. PMID: 23173132
22. DeGorter MK, Tirona RG, Schwarz UI, Choi Y-H, Dresser GK, Suskin N, et al. Clinical and Pharmacogenetic Predictors of Circulating Atorvastatin and Rosuvastatin Concentrations in Routine Clinical Care. Circulation: Cardiovascular Genetics. 2013; 6(4):400-8. doi: 10.1161/circgenetics.113.000099
23. Li X-N, Xu H-R, Chen W-L, Chu N-N, Zhu J-R. Pharmacokinetics of rosuvastatin in healthy Chinese volunteers living in China: A randomized, open-label, ascending single- and multiple-dose study. Clinical Therapeutics. 2010; 32(3):575-87. doi: 10.1016/j.clinthera.2010.03.015 PMID: 20399994
24. MacDonald PE. Signal integration at the level of ion channel and exocytotic function in pancreatic β-cells. American Journal of Physiology - Endocrinology and Metabolism. 2011; 301(6):E1065-E9. doi: 10.1152/ajpendo.00426.2011 PMID: 21934040
25. Banach M, Serban C, Ursoniu S, Rysz J, Muntner P, Toth PP, et al. Statin therapy and plasma coenzyme Q10 concentrations - A systematic review and meta-analysis of placebo-controlled trials. Pharmacological Research. 2015; 99:329-36. doi: 10.1016/j.phrs.2015.07.008 PMID: 26192349
26. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. The Lancet. 375(9716):735-42. doi: 10.1016/S0140-6736(09)61965-6
27. Yaluri N, Modi S, Lopez Rodriguez M, Stancakova A, Kuusisto J, Kokkola T, et al. Simvastatin Impairs Insulin Secretion by Multiple Mechanisms in MIN6 Cells. PLoS One. 2015; 10(11):e0142902. doi: 10.1371/journal.pone.0142902 PMID: 26561346; PubMed Central PMCID: PMC4641640.
28. Bugliani M, Syed F, Masini M, Marselli L, Suleiman M, Novelli M, et al. Direct effects of rosuvastatin on pancreatic human beta cells. Acta Diabetol. 2013; 50(6):983-5. doi: 10.1007/s00592-013-0465-y PMID: 23503985.
29. Zúñiga-Hertz JP, Rebelato E, Kassan A, Khalifa AM, Ali SS, Patel HH, et al. Distinct pathways of cholesterol biosynthesis impact on insulin secretion. Journal of Endocrinology. 2015; 224(1):75-84. doi: 10.1530/joe-14-0348 PMID: 25453115
30. Wang Y, Okamoto M, Schmitz F, Hofmann K, Sudhof TC. Rim is a putative Rab3 effector in regulating synaptic-vesicle fusion. Nature. 1997; 388(6642):593-8. PMID: 9252191
31. Coppola T, Magnin-Lüthi S, Perret-Menoud V, Gattesco S, Schiavo G, Regazzi R. Direct Interaction of the Rab3 Effector RIM with Ca2+Channels, SNAP-25, and Synaptotagmin. Journal of Biological Chemistry. 2001; 276(35):32756-62. doi: 10.1074/jbc.M100929200 PMID: 11438518
32. Kaeser PS, Deng L, Wang Y, Dulubova I, Liu X, Rizo J, et al. RIM Proteins Tether Ca2+ Channels to Presynaptic Active Zones via a Direct PDZ-Domain Interaction. Cell. 2011; 144(2):282-95. doi: 10.1016/j.cell.2010.12.029 PMID: 21241895
33. Grosshans BL, Ortiz D, Novick P. Rabs and their effectors: Achieving specificity in membrane traffic. Proceedings of the National Academy of Sciences. 2006; 103(32):11821-7. doi: 10.1073/pnas.0601617103
34. Iezzi M, Regazzi R, Wollheim CB. The Rab3-interacting molecule RIM is expressed in pancreatic β-cells and is implicated in insulin exocytosis. FEBS Letters. 2000; 474(1):66-70. doi: 10.1016/S0014-5793(00)01572-6 PMID: 10828453